Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 11/2006

01.11.2006 | Original Article

Tumour-expressed tissue factor inhibits cellular cytotoxicity

verfasst von: Chao Li, Lucy M. Colman, Mary E. W. Collier, Charlotte E. Dyer, John Greenman, Camille Ettelaie

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 11/2006

Einloggen, um Zugang zu erhalten

Abstract

Aims: The association between tissue factor (TF) expression and increased rate of tumour metastasis is well established. In this study, we have examined the hypothesis that the expression of TF by disseminated tumour cells confers protection against immune recognition and cytotoxicity. Materials and methods: A hybrid EGFP-TF protein was expressed in HT29 colon carcinoma and K562 lymphoblast cell lines. To assess the cytotoxic activity against tumour cells over-expressing TF, a novel method was used, based on the direct measurement of fluorescently labelled HT29 or K562 target cells. Results: Upon challenge with peripheral blood mononuclear cells (PBMC), tumour cells expressing TF partially evaded cellular cytotoxicity (Δ=15–40% reduction in cytotoxicity). Moreover, the influence of TF was not primarily dependent on its procoagulant function, although the inclusion of 20% (v/v) plasma did lower the rate of cytotoxicity against untransfected cells. However, expression of a truncated form of TF, devoid of the cytoplasmic domain, did not mediate any degree of inhibition of cytotoxicity, suggesting that the protective function of TF is principally due to this domain. Conclusions: We conclude that TF can promote immune evasion in tumour cells expressing this protein leading to increased survival and therefore metastatic rate in such cells.
Literatur
1.
Zurück zum Zitat Kirchhofer D, Nemerson Y (1996) Initiation of blood coagulation: the tissue factor/factor VIIa complex. Curr Opin Biotechnol 7:386–391PubMedCrossRef Kirchhofer D, Nemerson Y (1996) Initiation of blood coagulation: the tissue factor/factor VIIa complex. Curr Opin Biotechnol 7:386–391PubMedCrossRef
2.
Zurück zum Zitat Callander NS, Varki N, Rao LV (1992) Immunohistochemical identification of tissue factor in solid tumors. Cancer 70:1194–1201PubMedCrossRef Callander NS, Varki N, Rao LV (1992) Immunohistochemical identification of tissue factor in solid tumors. Cancer 70:1194–1201PubMedCrossRef
3.
Zurück zum Zitat Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RC (1995) Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 346:1004–1005PubMedCrossRef Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RC (1995) Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 346:1004–1005PubMedCrossRef
4.
Zurück zum Zitat Koomagi R, Volm M (1998) Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer 79:19–22PubMedCrossRef Koomagi R, Volm M (1998) Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer 79:19–22PubMedCrossRef
5.
Zurück zum Zitat Lawleed BA, Chisholm M, Francis JL (1999) Urinary tissue factor levels in patients with breast and colorectal cancer. J Pathol 187:291–294CrossRef Lawleed BA, Chisholm M, Francis JL (1999) Urinary tissue factor levels in patients with breast and colorectal cancer. J Pathol 187:291–294CrossRef
6.
Zurück zum Zitat Vrana JA., Stang MT, Grande JP, Getz MJ (1996) Expression of tissue factor in tumour stroma correlates with progression to invasive human breast Cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family. Cancer Res 56:5063–5070PubMed Vrana JA., Stang MT, Grande JP, Getz MJ (1996) Expression of tissue factor in tumour stroma correlates with progression to invasive human breast Cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family. Cancer Res 56:5063–5070PubMed
7.
Zurück zum Zitat Ueda C, Hirohata Y, Kihara Y, Nakamura H, Abe S, Akahane K, Okamoto K, Itoh H, Otsuki M (2001) Pancreatic cancer complicated by disseminated intravascular coagulation associated with production of tissue factor. J Gastroenterol 36:845–850 Ueda C, Hirohata Y, Kihara Y, Nakamura H, Abe S, Akahane K, Okamoto K, Itoh H, Otsuki M (2001) Pancreatic cancer complicated by disseminated intravascular coagulation associated with production of tissue factor. J Gastroenterol 36:845–850
8.
Zurück zum Zitat Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T, Ushio Y (1996) Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer 77:1877–1883PubMedCrossRef Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T, Ushio Y (1996) Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer 77:1877–1883PubMedCrossRef
9.
Zurück zum Zitat Abdulkadir SA, Carvalhal GF, Kaleem Z, Kisiel W, Humphrey PA, Catalona WJ, Milbrandt J (2000) Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 31:443–447PubMedCrossRef Abdulkadir SA, Carvalhal GF, Kaleem Z, Kisiel W, Humphrey PA, Catalona WJ, Milbrandt J (2000) Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 31:443–447PubMedCrossRef
10.
Zurück zum Zitat Nakasaki T, Wada H, Shigemori C, Miki C, Gabazza EC, Nobori T, Nakamura S, Shiku H. (2002) Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol 69:247–254PubMedCrossRef Nakasaki T, Wada H, Shigemori C, Miki C, Gabazza EC, Nobori T, Nakamura S, Shiku H. (2002) Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol 69:247–254PubMedCrossRef
11.
Zurück zum Zitat Shigenmori C, Wada H, Matsumoto K, Shioklu H, Nakamura S, Suzuki H (1998) Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemostas 80:894–898 Shigenmori C, Wada H, Matsumoto K, Shioklu H, Nakamura S, Suzuki H (1998) Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemostas 80:894–898
12.
Zurück zum Zitat Bierhaus A, Nawroth PP (2005) Coagulation, inflammation and immune response-an evolutionary conserved plan as cause for disseminated intravasal coagulation? Hamostaseologie 25:23–32PubMed Bierhaus A, Nawroth PP (2005) Coagulation, inflammation and immune response-an evolutionary conserved plan as cause for disseminated intravasal coagulation? Hamostaseologie 25:23–32PubMed
13.
Zurück zum Zitat Dvora HF, Senger DR, Dvorak AM (1983) Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev 2:41–73CrossRef Dvora HF, Senger DR, Dvorak AM (1983) Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev 2:41–73CrossRef
14.
Zurück zum Zitat Bardos H, Molnar P, Csecsei G, Adany R (1996) Fibrin deposition in primary and metastatic human brain tumors. Blood Coagula Fibrinolysis 7:536–548CrossRef Bardos H, Molnar P, Csecsei G, Adany R (1996) Fibrin deposition in primary and metastatic human brain tumors. Blood Coagula Fibrinolysis 7:536–548CrossRef
15.
Zurück zum Zitat Wojtukiewicz MZ, Zacharaski LR, Memoli VA (1990) Fibrinogen-fibrin transformation in situ in renal cell carcinoma. Anticancer Res 10:579–582PubMed Wojtukiewicz MZ, Zacharaski LR, Memoli VA (1990) Fibrinogen-fibrin transformation in situ in renal cell carcinoma. Anticancer Res 10:579–582PubMed
16.
Zurück zum Zitat Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskova M, Degen JL (2005) Platelets and fibrin (ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105:178–185PubMedCrossRef Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskova M, Degen JL (2005) Platelets and fibrin (ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105:178–185PubMedCrossRef
17.
Zurück zum Zitat Gunji Y, Lewis J, Gorelik E (1990) Fibrin formation inhibits the in vitro cytotoxic activity of human natural and lymphokine-activated killer cells. Blood Coagul Fibrinolysis 1:663–672PubMed Gunji Y, Lewis J, Gorelik E (1990) Fibrin formation inhibits the in vitro cytotoxic activity of human natural and lymphokine-activated killer cells. Blood Coagul Fibrinolysis 1:663–672PubMed
18.
Zurück zum Zitat Gorelik E (1992) Protective effect of fibrin on tumour metastasis. Fibrinolysis 6:35–38CrossRef Gorelik E (1992) Protective effect of fibrin on tumour metastasis. Fibrinolysis 6:35–38CrossRef
19.
Zurück zum Zitat Carr ME Jr, Sajer SA, Spaulding A (1992) Fibrin coating of bladder tumor cells (T24) is not protective against LAK cell cytotoxicity. J Lab Clin Med 119:132–138PubMed Carr ME Jr, Sajer SA, Spaulding A (1992) Fibrin coating of bladder tumor cells (T24) is not protective against LAK cell cytotoxicity. J Lab Clin Med 119:132–138PubMed
20.
Zurück zum Zitat Reijerkerk A, Meijers JC, Havik SR, Bouma BN, Voest EE, Gebbink MF (2004) Tumor growth and metastasis are not affected in thrombin-activatable fibrinolysis inhibitor-deficient mice. J Thromb Haemost 2:769–779PubMedCrossRef Reijerkerk A, Meijers JC, Havik SR, Bouma BN, Voest EE, Gebbink MF (2004) Tumor growth and metastasis are not affected in thrombin-activatable fibrinolysis inhibitor-deficient mice. J Thromb Haemost 2:769–779PubMedCrossRef
21.
Zurück zum Zitat Kunzelmann-Marche C, Satta N, Toti F, Zhang Y, Nawroth PP, Morrissey JH, Freyssinet JM. (2000) The influence exerted by a restricted phospholipid microenvironment on the expression of tissue factor activity at the cell plasma membrane surface. Thromb Haemost 83:282–289PubMed Kunzelmann-Marche C, Satta N, Toti F, Zhang Y, Nawroth PP, Morrissey JH, Freyssinet JM. (2000) The influence exerted by a restricted phospholipid microenvironment on the expression of tissue factor activity at the cell plasma membrane surface. Thromb Haemost 83:282–289PubMed
22.
Zurück zum Zitat Dietzen DJ, Jack GG, Page KL, Tetzloff TA, Hall CL, Mast AE. (2003) Localization of tissue factor pathway inhibitor to lipid rafts is not required for inhibition of factor VIIa/tissue factor activity. Thromb Haemost 89:65–73PubMed Dietzen DJ, Jack GG, Page KL, Tetzloff TA, Hall CL, Mast AE. (2003) Localization of tissue factor pathway inhibitor to lipid rafts is not required for inhibition of factor VIIa/tissue factor activity. Thromb Haemost 89:65–73PubMed
23.
Zurück zum Zitat Mulder AB, Smit JW, Bom VJ, Blom NR, Ruiters MH, Halie MR, van der Meer J. (1996) Association of smooth muscle cell tissue factor with caveolae. Blood 88:1306–1313PubMed Mulder AB, Smit JW, Bom VJ, Blom NR, Ruiters MH, Halie MR, van der Meer J. (1996) Association of smooth muscle cell tissue factor with caveolae. Blood 88:1306–1313PubMed
25.
Zurück zum Zitat Shoji M, Hancock WW, Abe K, Micko C, Casper KA, Baine RM, Wilcox JN, Danave I, Dillehay DL, Matthews E, Contrino J, Morrissey JH, Gordon S, Edgington TS, Kudryk B, Kreutzer DL, Rickles FR (1998) Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 152:399–411PubMed Shoji M, Hancock WW, Abe K, Micko C, Casper KA, Baine RM, Wilcox JN, Danave I, Dillehay DL, Matthews E, Contrino J, Morrissey JH, Gordon S, Edgington TS, Kudryk B, Kreutzer DL, Rickles FR (1998) Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 152:399–411PubMed
26.
Zurück zum Zitat Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, Stern DM, Nawroth PP (1994) Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 94:1320–1327PubMedCrossRef Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, Stern DM, Nawroth PP (1994) Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 94:1320–1327PubMedCrossRef
27.
Zurück zum Zitat Mueller B, Ruf W (1998) Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest 101:1372–1378PubMedCrossRef Mueller B, Ruf W (1998) Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest 101:1372–1378PubMedCrossRef
28.
Zurück zum Zitat Contrino J, Hair G, Kreutzer DL, Rickles FR (1996) In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 2:209–215PubMedCrossRef Contrino J, Hair G, Kreutzer DL, Rickles FR (1996) In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 2:209–215PubMedCrossRef
29.
Zurück zum Zitat Bromberg ME, Sundaram R, Homer RJ, Garen A, Konigsberg WH (1999) Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule. Thromb Haemost 82:88–92PubMed Bromberg ME, Sundaram R, Homer RJ, Garen A, Konigsberg WH (1999) Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule. Thromb Haemost 82:88–92PubMed
30.
Zurück zum Zitat Versteeg HH, Richel DJ, Peppelenbosch MP, Spek CA (2004) Concerted action of coagulation factors on cell survival. J Thromb Haemost 2:673–674PubMedCrossRef Versteeg HH, Richel DJ, Peppelenbosch MP, Spek CA (2004) Concerted action of coagulation factors on cell survival. J Thromb Haemost 2:673–674PubMedCrossRef
31.
Zurück zum Zitat Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A (1995) Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 92:8205–8209PubMedCrossRef Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A (1995) Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 92:8205–8209PubMedCrossRef
32.
Zurück zum Zitat Brunner KT, Mauel J, Cerottini JC, Chapuis B (1968) Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 14:181–196PubMed Brunner KT, Mauel J, Cerottini JC, Chapuis B (1968) Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 14:181–196PubMed
33.
Zurück zum Zitat Brown CE, Wright CL, Naranjo A, Vishwanath RP, Chang WC, Olivares S, Wagner JR, Bruins L, Raubitschek A, Cooper LJ, Jensen MC (2005) Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. J Immunol Methods 297:39–52PubMedCrossRef Brown CE, Wright CL, Naranjo A, Vishwanath RP, Chang WC, Olivares S, Wagner JR, Bruins L, Raubitschek A, Cooper LJ, Jensen MC (2005) Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. J Immunol Methods 297:39–52PubMedCrossRef
34.
Zurück zum Zitat Sorensen BB, Rao LV, Tornehave D, Gammeltoft S, Petersen LC (2003) Antiapoptotic effect of coagulation factor VIIa. Blood 102:1708–1715PubMedCrossRef Sorensen BB, Rao LV, Tornehave D, Gammeltoft S, Petersen LC (2003) Antiapoptotic effect of coagulation factor VIIa. Blood 102:1708–1715PubMedCrossRef
35.
Zurück zum Zitat Abe K, Shoji M, Chen J, Bierhaus A, Danave I, Micko C, Casper K, Dillehay DL, Nawroth PP, Rickles FR (1999) Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 96:8663–8668PubMedCrossRef Abe K, Shoji M, Chen J, Bierhaus A, Danave I, Micko C, Casper K, Dillehay DL, Nawroth PP, Rickles FR (1999) Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 96:8663–8668PubMedCrossRef
36.
Zurück zum Zitat Versteeg HH, Peppelenbosch MP, Spek CA (2003) Tissue factor signal transduction in angiogenesis. Carcinogenesis 24:1009–1013PubMedCrossRef Versteeg HH, Peppelenbosch MP, Spek CA (2003) Tissue factor signal transduction in angiogenesis. Carcinogenesis 24:1009–1013PubMedCrossRef
37.
Zurück zum Zitat Paborsky LR, Tate KM, Harris RJ, Yansura DG, Band L, McCray G, Gorman CM, O’Brien DP, Chang JY, Swartz JR, Fung VP, Thomas JN, Vehar GA (1989) Purification of recombinant human tissue factor. Biochemistry 28:8072–8077PubMedCrossRef Paborsky LR, Tate KM, Harris RJ, Yansura DG, Band L, McCray G, Gorman CM, O’Brien DP, Chang JY, Swartz JR, Fung VP, Thomas JN, Vehar GA (1989) Purification of recombinant human tissue factor. Biochemistry 28:8072–8077PubMedCrossRef
38.
Zurück zum Zitat Paborsky LR, Caras IW, Fisher KL, Gorman CM (1991) Lipid association, but not the transmembrane domain, is required for tissue factor activity. Substitution of the transmembrane domain with a phosphatidylinositol anchor. J Biol Chem 266:21911–21916PubMed Paborsky LR, Caras IW, Fisher KL, Gorman CM (1991) Lipid association, but not the transmembrane domain, is required for tissue factor activity. Substitution of the transmembrane domain with a phosphatidylinositol anchor. J Biol Chem 266:21911–21916PubMed
39.
Zurück zum Zitat Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahamed J, Dorfleutner A, Carmeliet P, Mueller BM, Friedlander M, Ruf W (2004) Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 10:502–509PubMedCrossRef Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahamed J, Dorfleutner A, Carmeliet P, Mueller BM, Friedlander M, Ruf W (2004) Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 10:502–509PubMedCrossRef
40.
Zurück zum Zitat Pawlinski R, Pedersen B, Erlich J, Mackman N (2004) Role of tissue factor in haemostasis, thrombosis, angiogenesis and inflammation: lessons from low tissue factor mice. Thromb Haemostas 92:444–450 Pawlinski R, Pedersen B, Erlich J, Mackman N (2004) Role of tissue factor in haemostasis, thrombosis, angiogenesis and inflammation: lessons from low tissue factor mice. Thromb Haemostas 92:444–450
41.
Zurück zum Zitat Watanabe T, Yasuda M, Yamamoto T (1999) Angiogenesis induced by tissue factor in vitro and in vivo. Thrombosis Res 96:183–189CrossRef Watanabe T, Yasuda M, Yamamoto T (1999) Angiogenesis induced by tissue factor in vitro and in vivo. Thrombosis Res 96:183–189CrossRef
42.
Zurück zum Zitat James NJ, Ettelaie C, Bruckdorfer KR (2002) Inhibition of tissue factor activity reduces the density of cellular network formation in an in vitro model of angiogenesis. Biochem Soc Trans 30:217–221PubMedCrossRef James NJ, Ettelaie C, Bruckdorfer KR (2002) Inhibition of tissue factor activity reduces the density of cellular network formation in an in vitro model of angiogenesis. Biochem Soc Trans 30:217–221PubMedCrossRef
43.
Zurück zum Zitat Camerer E, Gjernes E, Wiiger M, Pringle S, Prydz H (2000) Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J Biol Chem 275:6580–6585PubMedCrossRef Camerer E, Gjernes E, Wiiger M, Pringle S, Prydz H (2000) Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J Biol Chem 275:6580–6585PubMedCrossRef
44.
Zurück zum Zitat Poulsen LK, Jacobsen N, Sorensen BB, Bergenhem NC, Kelly JD, Foster DC, Thastrup O, Ezban M, Petersen LC (1998) Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor. J Biol Chem 273:6228–6232PubMedCrossRef Poulsen LK, Jacobsen N, Sorensen BB, Bergenhem NC, Kelly JD, Foster DC, Thastrup O, Ezban M, Petersen LC (1998) Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor. J Biol Chem 273:6228–6232PubMedCrossRef
45.
Zurück zum Zitat Hartzell S, Ryder K, Lanahan A, Lau LF, Nathan D (1989) A growth factor-responsive gene of murine BALB/c 3T3 cells encodes a protein homologous to human tissue factor. Mol Cell Biol 9:2567–2573PubMed Hartzell S, Ryder K, Lanahan A, Lau LF, Nathan D (1989) A growth factor-responsive gene of murine BALB/c 3T3 cells encodes a protein homologous to human tissue factor. Mol Cell Biol 9:2567–2573PubMed
46.
Zurück zum Zitat Versteeg HH, Spek CA, Peppelenbosch MP, Richel DJ (2004) Tissue factor and cancer metastasis: the role of intracellular and extracellular signaling pathways. Mol Med 10:6–11PubMedCrossRef Versteeg HH, Spek CA, Peppelenbosch MP, Richel DJ (2004) Tissue factor and cancer metastasis: the role of intracellular and extracellular signaling pathways. Mol Med 10:6–11PubMedCrossRef
47.
Zurück zum Zitat Versteeg HH, Spek CA, Richel DJ, Peppelenbosch MP (2004) Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene 23:410–417PubMedCrossRef Versteeg HH, Spek CA, Richel DJ, Peppelenbosch MP (2004) Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene 23:410–417PubMedCrossRef
48.
Zurück zum Zitat Versteeg HH, Spek CA, Slofstra SH, Diks SH, Richel DJ, Peppelenbosch MP (2004) FVIIa: TF induces cell survival via G12/G13-dependent Jak/STAT activation and BclXL production. Circ Res 94:1032–1040PubMedCrossRef Versteeg HH, Spek CA, Slofstra SH, Diks SH, Richel DJ, Peppelenbosch MP (2004) FVIIa: TF induces cell survival via G12/G13-dependent Jak/STAT activation and BclXL production. Circ Res 94:1032–1040PubMedCrossRef
Metadaten
Titel
Tumour-expressed tissue factor inhibits cellular cytotoxicity
verfasst von
Chao Li
Lucy M. Colman
Mary E. W. Collier
Charlotte E. Dyer
John Greenman
Camille Ettelaie
Publikationsdatum
01.11.2006
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 11/2006
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-006-0130-1

Weitere Artikel der Ausgabe 11/2006

Cancer Immunology, Immunotherapy 11/2006 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.